Abstract
Simple Summary In 2017, two chimeric antigen receptor-T (CAR-T) therapies were approved by the FDA for advanced/resistant lymphoma and acute lymphobla......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
